Lilly co-funds China's Innovent in biologics expansion
This article was originally published in Scrip
Executive Summary
The regional venture aim of Eli Lilly has come in to participate in a second round of venture capital raised by the Chinese bioventure Innovent Biologics. Innovent is positioning itself as a developer and international supplier of monoclonal antibodies and biosimilars, in a strategy that won the company $30 million in startup capital late last year from investors including Fidelity Growth Partners Asia and the China-Singapore Suzhou Industrial Park (Suzhou BioBay), where Innovent is located.